Top

Carlos Kamiya Matsuoka, M.D.

Department of Neuro-Oncology, Division of Cancer Medicine

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Assistant Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2007	Major National University of San Marcos, Lima, PE, MD

Postgraduate Training

2013-2015	Clinical Fellowship, Neuro-Oncology, UTMD Anderson Cancer Center, Houston, Texas
2012-2013	Chief Resident, Neurology, University of Texas Medical Branch, Galveston, Texas
2010-2013	Clinical Residency, Neurology, University of Texas Medical Branch, Galveston, Texas
2009-2010	Clinical Internship, Internal Medicine, Texas Tech University, El Paso, Texas

Licenses & Certifications

2023	Bilingual Qualification Program
2017	United Council for Neurologic Subspecialties (UCNS) - Neuro-Oncology
2015	Texas
2015	American Board of Psychiatry and Neurology

Experience & Service

Faculty Academic Appointments

Assistant Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2022

Administrative Appointments/Responsibilities

MD Anderson Disease Site Committee member, UTMD Anderson Cancer Center, Houston, TX, 2025 - Present

MDA Cancer Network Adjunct Appointment Workgroup, CNS representative Division of Cancer Medicine, UTMD Anderson Cancer Center, Houston, TX, 2024 - Present

MDA Cancer Network Research Director, UTMD Anderson Cancer Center, Houston, Texas, 2024 - Present

Community Outreach Engagement and Cancer Neuroscience Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present

Acute Care Procedure Team, Department of Neuro-Oncology, Revision of Standardized Protocol for Lumbar Puncture and Intrathecal Chemotherapy Administration, Houston, 2019 - Present

Other Professional Positions

Poster Awards Committee, SNO, New Orleans, LA, 2018

Team Leader, Clinica Alemana, Santiago, 2018 - Present

Member, CERN (Collaborative Ependymoma Research Network), Houston, TX, 2018 - Present

Principal Investigator, NIH BTTC (Brain Tumor Trials Collaborative), Bethesda, MD, 2018 - Present

Principal Investigator, NCI-CONNECT, NIH, Bethesda, MD, 2018 - Present

Member, Alliance for Clinical Trials in Oncology, Chicago, IL, 2017 - Present

Intramural Institutional Committee Activities

Member, Institutional Committee, International Trainee Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

Member, Institutional Committee, Undergrad Research Training Program, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 2024 - Present

Member, Institutional Committee, Elsevier ClinicalPath Disease Site Committee Representatives -CNS, The University of Texas MD Anderson Cancer Center, 2024 - Present

Member, Institutional Committee, Institutional Review Board (IRB), IRB3, The University of Texas MD Anderson Cancer Center, 2023 - 2025

Extramural Institutional Committee Activities

Member, Institutional Committee, Neuro-Oncology moderator, MDA Cancer Network, First retreat 2023, The University of Texas MD Anderson Cancer Center, 2023

Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2022 - 2025

Liaison, Neurosciences/ Neuro-Oncology Research Program and Community Outreach and Engagement, The University of Texas MD Anderson Cancer Center, 2022 - Present

Committee Member, Li-Fraumeni Syndrome Education And Early Detection, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2020 - 2025

Committee Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2023

Committee Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Committee Member, Faculty Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Honors & Awards

2024 - Present	Melvin L. Samuels Award for Excellence in Patient Care, UTMD Anderson Cancer Center
2023 - Present	Top 1% performer with a perfect score nationally on CAHPS measures, UTMD Anderson Cancer Center
2019	Melvin L. Samuels Award for Excellence in Patient Care, MD Anderson Cancer Center
2019	Merit Award, European Society for Medical Oncology (ESMO) Congress
2016	Cornelius G. Dyke Memorial Award, American Society of Neuroradiology (ASNR)
2014	William James Miller Endowed Fellowship Award, MD Anderson Cancer Center
2013	Resident Research Award, University of Texas Medical Branch
2013	Annual Meeting Resident Scholarship, American Academy of Neurology
2013	Outstanding Overall Resident Award Nomination, University of Texas Medical Branch
2012 - 2013	Outstanding Neurology Resident of the Year Award, University of Texas Medical Branch
2010	Best Overall Poster, Texas Tech University – William Beaumont Hospital
2008	Harrison Senior Citizen Center Distinguished Service Award, Harrison Senior Citizen Center, NJ
2007	Red Cross Distinguished Service Award, Red Cross, Lima Peru
2005	20th International Conference, University of Panama Research Prize, University of Panama
2005	Annual Scholarship for Excellence, Hipolito Unanue Foundation
2001 - 2002	Abeefe Bristol – Myers Squibb National Research Prize in Medicine, Bristol Myers Squibb Laboratory

Professional Memberships

Brain Tumor Trials Collaborative (BTTC)

2018 - Present

Harris County Medical Society (HCMS)

2015 - Present

Harris County Medical Society

2015 - Present

Society for Neuro-Oncology (SNO)

2014 - Present

American Academy of Neurology (AAN)

2010 - Present

Texas Medical Association (TMA)

2009 - Present

American College of Physicians (ACP)

2009

National Medical Association (CMP)

2007 - Present

Student Medical Association (CEM)

2000 - 2007

Scientific Society of San Fernando

2000 - 2007

Selected Presentations & Talks

Regional Presentations

2024. Accelerated tumor progression among glioma patients after COVID-19 infection Peer-reviewed conference presentation, Scientific Highlights. MD Anderson Town Hall. Houston, TX, US.
2022. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. Conference. Houston, TX, US.

National Presentations

2025. NCOG-22 Gliomas associated with Li-Fraumeni Syndrome. Poster. SNO 30th Annual Meeting. Honolulu, Hawaii, US.
2025. DNAR-08 Phase I Trial of Peposertib (DNA-PK inhibitor) Plus Radiation in Newly Diagnosed MGMT-Unmethylated Glioblastoma, Updated Clinical, Radiographic, and Biomarker Outcomes. Poster. SNO 30th Annual Meeting. Honolulu, Hawaii, US.
2025. CTP-05 VAL-083 for treatment of Histone H3-Wild Type Diffuse Midline Glioma. Poster. SNO 30th Annual Meeting. Honolulu, Hawaii, US.
2025. CTNI-58 Updated results of Phase 3 STELLAR trial: Eflornithine improves overall survival and blinded independent central review determined progression free survival in patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma. Poster. SNO 30th Annual Meeting. Honolulu, Hawaii, US.
2025. TIP-21 Phase I trial of mesenchymal stem cells carrying Delta-24-RGD given intraarterially in recurrent glioma: Early report. Poster. SNO 30th Annual Meeting. Honolulu, Hawaii, US.
2025. BIOM-63 Molecular features of aggressive MMR deficiency brain tumors and response to immunotherapy. Poster. SNO 30th Annual Meeting. Honolulu, Hawaii, US.
2025. Targeted therapy in low- and high-grade Glioma. Conference. 21st World Congress of SBMT 2024. Los Angeles, CA, US.
2025. Application of 200 kHz Tumor Treating Fields (TTFields) in Patients with Infratentorial High-grade Glioma: Case Series. Conference. 21st World Congress of SBMT 2024. Los Angeles, CA, US.
2024. Precision Medicine in Neuro-Oncology for the Management of Glioblastoma. Conference. 21st World Congress of SBMT 2024. Los Angeles, TX, US.
2023. RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports. Conference. RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports. Orlando, FL, US.
2023. VAL-083 in patients with recurrent glioblastoma treated under expanded access program. Conference. VAL-083 in patients with recurrent glioblastoma treated under expanded access program. Orlando, FL, US.
2023. Immunophenotyping of human brain tumors reveals myeloid cell mediated anti-glioma axis. Conference. Immunophenotyping of human brain tumors reveals myeloid cell mediated anti-glioma axis. Orlando, FL, US.
2022. Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access. Conference. Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access. Tampa, US.
2022. Immunophenotyping of brain tumors identifies interferon enriched phagocytes in human gliomas. Conference. Immunophenotyping of brain tumors identifies interferon enriched phagocytes in human gliomas. Boston, US.
2022. VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program. Conference. VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program. Tampa, US.
2020. Transcriptionally defined immune contexture in human gliomas at single-cell resolution. Conference. 25TH Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Virtual Meeting, US.
2020. Efficacy of pembrolizumab in patients with pituitary carcinoma: Results from a Phase II study. Conference. Efficacy of pembrolizumab in patients with pituitary carcinoma: Results from a Phase II study. Houston, TX, US.
2020. A Snapshot of the impact of COVID-19 on patient with nervous system tumors. Conference. A Snapshot of the impact of COVID-19 on patient with nervous system tumors. Houston, TX, US.
2020. A retrospective study of treatment strategies and outcomes in WHO grade II and III isocitrate dehydrogenase (IDH) wild-type astrocytoma. Conference. A retrospective study of treatment strategies and outcomes in WHO grade II and III isocitrate dehydrogenase (IDH) wild-type astrocytoma. Houston, TX, US.
2020. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-Unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Conference. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-Unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Houston, TX, US.
2020. Molecular, histologic and clinical characteristics of oligodendrogliomas: A multi-institutional retrospective study. Conference. Molecular, histologic and clinical characteristics of oligodendrogliomas: A multi-institutional retrospective study. Houston, TX, US.
2020. Long-Term Use Of Everolimus Plus Octreotide For Recurrent Intracranial Or Spinal Meningioma: A Single Institution Experience. Conference. Long-Term Use Of Everolimus Plus Octreotide For Recurrent Intracranial Or Spinal Meningioma: A Single Institution Experience. Houston, TX, US.
2020. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (ATEZO) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Conference. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (ATEZO) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Houston, TX, US.
2020. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-Unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Proceedings:. Conference. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-Unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Proceedings:. Philadelphia, US.
2019. Unique concurrent association of somatic and germline NF1 mutations with germline mismatch repair mutations in pediatric glioblastoma multiforme. Conference. Unique concurrent association of somatic and germline NF1 mutations with germline mismatch repair mutations in pediatric glioblastoma multiforme. Phoenix, AZ, US.
2019. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Conference. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Phoenix, AZ, US.
2019. Improvement of Leptomeningeal Disease Following Infectious Meningitis. Conference. Improvement of Leptomeningeal Disease Following Infectious Meningitis. Phoenix, AZ, US.
2019. Intrathecal Trastuzumab plus/minus IT Topotecan for Patients with HER2+ Breast Cancer and Leptomeningeal Metastasis. Conference. Intrathecal Trastuzumab plus/minus IT Topotecan for Patients with HER2+ Breast Cancer and Leptomeningeal Metastasis. New York, NY, US.
2019. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Conference. The Society for Neuro-Oncology's Inaugural Conference on Brain Metastases. New York, NY, US.
2019. Genetic and Immune Profiling for Potential Therapeutic Targets in Adult Human Craniopharyngioma. Conference. 24th Neuro-Tumor Club Meeting at AACR. Atlanta, GA, US.
2019. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT unmethylated, bevacizumab-naïve recurrent glioblastoma. Conference. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT unmethylated, bevacizumab-naïve recurrent glioblastoma. Atlanta, GA, US.
2018. A Window-of-opportunity clinical trial of pembrolizumab in recurrent glioblastoma patients. Conference. 23 Annual Scientific Meeting of the Society for Neuro-Oncology. NewOrleans, LA, US.
2018. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Conference. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. New Orleans, LA, US.
2018. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-Unmethylated, Bevacizumab-Naïve Recurrent Glioblastoma. Conference. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-Unmethylated, Bevacizumab-Naïve Recurrent Glioblastoma. New Orleans, LA, US.
2018. INNV-44 Gram positive colonization of the Ommaya reservoir; treatment recommendations with clinical examples. Conference. INNV-44 Gram positive colonization of the Ommaya reservoir; treatment recommendations with clinical examples. New Orleans, LA, US.
2018. Safety run-in results of a phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Conference. 23 Annual Scientific Meeting of the Society for Neuro-Oncology, US.
2018. A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells (CMV-TC) for Glioblastoma: Dose Escalation and Correlative Results. Conference. 23 Annual Scientific Meeting of the Society for Neuro-Oncology. New Orleans, LA, US.
2018. Magnetic Resonance Imaging Vector Machine Learning Predicts the Glioma Hypermutation Phenotype. Conference. Tumor Section Satellite Symposium. Houston, TX, US.
2018. A unique MRI-based radiomic signature predicts hypermutated glioma genotype. Conference. A unique MRI-based radiomic signature predicts hypermutated glioma genotype. Chicago, IL, US.
2018. A phase I/II clinical trial of autologous CMV-specific cytotoxic T cells (CMV-TC) for glioblastoma: Dose escalation results. Conference. A phase I/II clinical trial of autologous CMV-specific cytotoxic T cells (CMV-TC) for glioblastoma: Dose escalation results. Chicago, IL, US.
2018. Phase II study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naive recurrent glioblastoma, MGMT-unmethylated. Conference. Phase II study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naive recurrent glioblastoma, MGMT-unmethylated. Chicago, IL, US.
2018. A Radiomic signature predicts the tumor mutation burden status (Hypermutation) in glioma patients. Conference. 2018 The Cancer Imaging and Intervention Conference,, US.
2018. Paroxysmal Singultus as the result of Brainstem Histoplasmosis. Conference. Paroxysmal Singultus as the result of Brainstem Histoplasmosis. Los Angeles, CA, US.
2018. Gliomatosis Cerebri: Predispositions and Predictors of Behavior. Poster Presentation. Conference. Gliomatosis Cerebri: Predispositions and Predictors of Behavior. Poster Presentation, US.
2018. Glioblastoma that Arises from Tumefactive Multiple Sclerosis, Poster presentation. Conference. Glioblastoma that Arises from Tumefactive Multiple Sclerosis, Poster presentation. Los Angeles, CA, US.
2017. The Natural Course of Hypermutator Gliomas. Conference. 22 Annual Scientific Meeting of the Society for Neuro-Oncology. San Francisco, CA, US.
2017. Increased mutation burden (Hypermutation) in gliomas is associated with a unique radiomic texture signature in magnetic resonance imaging. Conference. 22 Annual Scientific Meeting of the Society for Neuro-Oncology. San Francisco, CA, US.
2017. Association of clinical phenotype and treatment history with survival in adult brainstem glioblastoma. Conference. Association of clinical phenotype and treatment history with survival in adult brainstem glioblastoma. Chicago, IL, US.
2016. Ependymomas arising outside of the central nervous system: A case series. Conference. Ependymomas arising outside of the central nervous system: A case series. Scottsdale, AZ, US.
2016. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. Conference. 54th Annual Meeting of the American Society of Neuroradiology. Washington, DC, US.
2015. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. Conference. 20tH Annual Scientific Meeting of the Society for Neuro-Oncology. San Antonio, TX, US.
2015. Carpal Tunnel Syndrome Assessment in Elderly Patients - Problems and Potential Solutions. Conference. American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 62nd Annual Meeting. Honolulu, HI, US.
2015. Expression of Csk is associated with its methylation status in colorectal cancer cells. Conference. Digestive Disease Week. Washington, DC, US.
2015. Electrographic Patterns In Patients With Posterior Reversible Encephalopathy Syndrome (PRES) And Seizures. Conference. 2015 Annual Meeting of the American Academy of Neurology. Washington, DC, US.
2015. Encephaloclastic cyst induced by intraventricular topotecan. Conference. 2015 Annual Meeting of the American Academy of Neurology (AAN). Washington, DC, US.
2015. Atypical isolated nuclear oculomotor nerve syndrome: A diagnostic challenge. Conference. 2015 Annual Meeting of the American Academy of Neurology. Washington, DC, US.
2014. Primary Brain Tumors and Posterior Reversible Encephalopathy Syndrome. Conference. 19TH Annual Scientific Meeting of the Society for Neuro-Oncology. Miami, FL, US.
2014. Temozolomide-based therapy for the management of progressive pituitary carcinoma. Conference. 19TH Annual Scientific Meeting of the Society for Neuro-Oncology. Miami, FL, US.
2014. Myelopathy following intrathecal chemotherapy: a case series in adults. Conference. 19TH Annual Scientific Meeting of the Society for Neuro-Oncology. Miami, FL, US.
2014. Primary Natural Killer/T-cell Lymphoma Presenting as Leptomeningeal Disease. Conference. 2014 Annual Meeting of the American Academy of Neurology. Philadelphia, PA, US.
2014. Atypical Neurological Complications of Ipilimumab Therapy in Patients with Metastatic Melanoma. Conference. 2014 Annual Meeting of the American Academy of Neurology. Philadelphia, PA, US.
2014. Refractory IgG4-related intracranial hypertrophic pachymeningitis. Conference. 2014 Annual Meeting of the American Academy of Neurology. Philadelphia, PA, US.
2013. B lymphoblastic leukemia/lymphoma presenting as fifth and seventh cranial nerve palsy. Conference. 2013 Annual Meeting of the American Academy of Neurology. San Diego, CA, US.
2012. A case series of clinical manifestations, treatments, and outcomes. Conference. 2012 Annual Meeting of the American Academy of Neurology. New Orleans, LA, US.
2012. Posterior reversible encephalopathy syndrome in cancer patients. Conference. 2012 Annual Meeting of the American Academy of Neurology. New Orleans, LA, US.
2001. Posterior reversible encephalopathy syndrome in cancer patients. Conference. 16 Annual Scientific Meeting of the Society for Neuro-Oncology (SNO). Orange County, CA, US.

International Presentations

2021. Neuro-Oncologic Genetic Tumor Syndromes – Advances in Management. Conference. Neuro-Oncologic Genetic Tumor Syndromes – Advances in Management. Santiago, CL.
2020. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Conference. 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, US.
2020. A Phase I/II Clinical Trial of Autologous CMV-Specific T cells in Glioblastoma (GBM) Patients Reveals a Lack of Immune Effector Function. Conference. 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, US.
2019. Effective in Hypermutator Glioblastomas with Somatic or Germline mutations. Conference. European Society for Medical Oncology (ESMO). Barcelona, ES.
2019. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Conference. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Vienna, AT.
2018. The natural course of hypermutator gliomas. Conference. 2018 American Society of Clinical Oncology Annual Meeting. Chicago, US.
2016. Gliomatosis, to Be or Not to Cerebri. Conference. Gliomatosis, to Be or Not to Cerebri. Vancouver, CA.
2016. Neurolymphomatosis and Anti-MAG Mononeuritis Multiplex in a Patient with Two Hematologic Malignancies. Conference. Neurolymphomatosis and Anti-MAG Mononeuritis Multiplex in a Patient with Two Hematologic Malignancies. Vancouver, CA.
2015. Outcomes after hospitalization in patients with recurrent glioblastoma. Conference. 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, US.
2014. Primary Natural Killer/T-cell Lymphoma Presenting as Leptomeningeal Disease. Conference. 2014 Joint Congress of European Neurology. Istanbul, TR.
2014. Impact of adverse effects of bevacizumab on survival outcomes of patients with recurrent glioblastoma. Conference. 2014 American Society of Clinical Oncology Annual Meeting. Chicago, US.
2014. Refractory IgG4-related intracranial hypertrophic pachymeningitis. Conference. 2014 Joint Congress of European Neurology. Istanbul, TR.
2005. Biological accidents in medical students of the Major National University of San Marcos: prevalence, mechanisms and risk factors. 20th International Conference. Conference. Latin American Federation of Scientific Societies of Medical Students, PA.
2005. Perception of the Medical Students and Attending Physicians of the Major National University of San Marcos about Animal Experimentation, 8 Annual Regional Scientific Meeting. Conference. Perception of the Medical Students and Attending Physicians of the Major National University of San Marcos about Animal Experimentation, 8 Annual Regional Scientific Meeting. Lima, PE.
2002. Anatomic variants of Celiac Trunk. 17 Annual Meeting of the Scientific Society of Medical Students. Conference. Anatomic variants of Celiac Trunk. 17 Annual Meeting of the Scientific Society of Medical Students. Lima, PE.
2002. Citoprotective effect of the epidermic growth factor in renal ischemia reperfusion injury. Conference. Citoprotective effect of the epidermic growth factor in renal ischemia reperfusion injury. Lima, PE.
2001. Protein-Energetic Malnutrition of the mother during the prenatal and postnatal period produces alterations in the development of offspring’s brain. Conference. Protein-Energetic Malnutrition of the mother during the prenatal and postnatal period produces alterations in the development of offspring’s brain. Lima, PE.

Formal Peers

2015. Posterior Reversible Encephalopathy Syndrome in Cancer. Visiting. New York, NY, US.
2013. Leptomeningeal Disease. Visiting. Galveston, TX, US.
2012. Street Drugs and Neuropharmacology. Visiting. Houston, TX, US.
2012. Posterior Reversible Encephalopathy Syndrome. Visiting. Galveston, TX, US.
2010. Central giant-cell granuloma. Visiting, TX, US.
2010. Leptomeningeal Disease. Visiting, TX, US.

Less

Grant & Contract Support

Date:	2022 - 2024
Title:	Ulixertinib for recurrent NF1 gliomas and CIC-mutant oligodendrogliomas
Funding Source:	Swim Across America
Role:	Principal Investigator-MDACC

Date:	2021 - 2026
Title:	Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	2020-0904

Title:	Ulixertinib for recurrent NF1 gliomas and CIC-mutant oligodendrogliomas
Funding Source:	BVD
Role:	Principal Investigator-MDACC

Title:	The natural course of hypermutator gliomas, Philanthropic Fund for Research
Funding Source:	Philanthropic fund Research
Role:	Principal Investigator-MDACC

Selected Publications

Peer-Reviewed Articles

Yeboa, DN, Whitfield, BT, Lin, R, Ejezie, CL, Swanson, T, Beckham, TH, Wang, C, De, BS, Perni, S, Tom, MC, Li, J, McGovern, SL, Harrison, R, Majd, NK, Puduvalli, VK, Aaroe, AE, Loghin, ME, O'Brien, BJ, Patel, AD, Patel, C, Wefel, JS, Taslicay, CA, Gule-Monroe, MK, Paulino, AC, McAleer, MF, Grosshans, DR, Ghia, AJ, Jiang, W, Chung, C, Maor, MM, Yang, CH, Gubbiotti, M, Kamiya Matsuoka, C, Ballester, L, Weathers, S, Huse, J. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses. Journal of neuro-oncology 176(1), 2026. e-Pub 2026. PMID: 41191157.
Brenner, AJ, Patel, TR, Bao, A, Phillips, WT, Michalek, J, Youssef, M, Weinberg, J, Kamiya Matsuoka, C, Hedrick, MH, LaFrance, N, Moore, M, Floyd, JR. Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40055350.
Garcia, CR, Highsmith, KN, Knight, SR, Andrade, IP, Leung, CH, Puduvalli, VK, Kamiya Matsuoka, C. Single center experience of IDH inhibitors in recurrent high-grade gliomas. Journal of neuro-oncology 175(2):837-844, 2025. e-Pub 2025. PMID: 40748516.
Weathers S, Li X, Zhu H, Damania AV, Knafl M, McKinley B, Lin H, Harrison RA, Majd NK, O’Brien BJ, Penas-Prado M, Loghin M, Kamiya-Matsuoka C, Yung W, Solis Soto LM, Maru DM, Wistuba I, Parra Cuentas ER, Hernandez S, Futreal A, Wargo JA, Schulze K, Darbonne WC, Ajami NJ, Woodman SE, de Groot JF. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial. Nat Commun 16(1):3950, 2025. e-Pub 2025. PMID: 40289138.
Garcia, CR, Robertson, IJ, Gregory, TA, Zahid, A, Amini, B, Kamiya Matsuoka, C, Tummala, S. Differential diagnosis in immune checkpoint inhibitors neurotoxicity. Journal of Neurology 272(2), 2025. e-Pub 2025. PMID: 39812686.
Gupta, P, Dang, M, Oberai, S, Migliozzi, S, Trivedi, R, Kumar, G, Peshoff, MM, Milam, N, Ahmed, A, Bojja, K, Tran, TM, Gumin, J, Kamiya Matsuoka, C, Huse, J, Cox, K, Li, J, Shehwana, H, Sheth, SA, Saxon, R, Baohua, S, Parker Kerrigan, BC, Maheshwari, A, Parra Cuentas, ER, Navin, N, Heimberger, AB, Lang Jr, FF, Iavarone, A, Dwyer, KC, Wang, L, Bhat, KP. Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. Neuro-oncology 26(12):2239-2255, 2024. e-Pub 2024. PMID: 39126294.
Ozkizilkaya, HI, Vinocha, A, Dono, A, Ogunbona, OB, Toruner, GA, Aung, PP, Kamiya Matsuoka, C, Esquenazi, Y, DeMonte, F, Ballester, LY. MTAP and p16 IHC as Markers for CDKN2A/B Loss in Meningiomas. Cancers 16(19), 2024. e-Pub 2024. PMID: 39409918.
Sloan AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N, Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M, Mehta MP. NRG-BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma. Neuro-Oncology 26(9):1628-1637, 2024. PMID: 38874333.
Sloan, AE, Winter, KA, Gilbert, MR, Aldape, K, Choi, S, Wen, PY, Butowski, N, Iwamoto, FM, Raval, RR, Voloschin, AD, Kamiya Matsuoka, C, Won, M, Mehta, MP. NRG-BN002. Neuro-oncology 26(9):1628-1637, 2024. e-Pub 2024. PMID: 38874333.
Sloan AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N, Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M, Mehta MP. NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma. Neuro Oncol 26(9):1628-1637, 2024. e-Pub 2024. PMID: 38874333.
Gregory, TA, Knight, SR, Aaroe, AE, Highsmith, KN, Janatpour, ZC, O’Brien, BJ, Majd, NK, Loghin, ME, Patel, C, Weathers, S, Puduvalli, VK, Kamiya Matsuoka, C. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma. Neuro-Oncology Practice 11(4):475-483, 2024. e-Pub 2024. PMID: 39006516.
Dasgupta, P, Ou, A, Lin, Y, Gregory, TA, Alfaro-Munoz, KD, Yuan, Y, Afshar-Khargan, V, Kamiya Matsuoka, C, Rousseau, JF, Majd, NK. The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab. Journal of neuro-oncology 167(1):181-188, 2024. e-Pub 2024. PMID: 38372903.
Lam K, Kamiya-Matsuoka C, Slopis JM, McCutcheon IE, Majd NK. Therapeutic Strategies for Gliomas Associated with Cancer Predisposition Syndromes. JCO Precision Oncology 8, 2024. PMID: 38394467.
Majd, NK, Yeboa, DN, Wang, S, Weathers, S, Yuan, Y, Al Anssari, H, Kamiya Matsuoka, C, O'Brien, BJ, Aaroe, AE, Patel, C, Dagher, SA, Wintermark, M, Ferguson, SD, Puduvalli, VK, Liu, SJ, Raleigh, D, de Groot, JF. Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma. Journal of Clinical Oncology 42(16_suppl):2076, 2024. e-Pub 2024.
Brastianos, PK, Dooley, KE, Geyer, S, Gerstner, E, Kaufmann, TJ, Iafrate, AJ, Milhem, MM, Welch, M, Kaley, T, Drappatz, J, Chan, A, Kumthekar, P, Kamiya Matsuoka, C, Strowd, RE, Cohen, A, Jaeckle, KA, Robell, L, Santagata, S, Barker, FG, Galanis, E. Alliance A071401. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
Rubino F, Schur S, McGovern SL, Kamiya-Matsuoka C, DeMonte F, Raza SM. Impact of salvage surgery with or without reirradiation for skull base meningiomas recurring after prior radiotherapy. J Neurosurg 139(3):1-12, 2023. e-Pub 2023. PMID: 36738459.
Rodriguez A, Kamiya-Matsuoka C, Majd NK. The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors. Curr Oncol 30(6):5279-5298, 2023. e-Pub 2023. PMID: 37366884.
Kamiya Matsuoka C, Ho WJ, Thomas JV, Raghav KP, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You Y, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol 41(12):2181-2190, 2023. e-Pub 2023. PMID: 36623241.
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol 41(12):2181-2190, 2023. e-Pub 2023. PMID: 36623241.
de Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien BJ, Weathers SP, Kamiya-Matsuoka C, Majd NK, Harrison RA, Fuller GN, Huse J, Long JP, Sawaya R, Rao G, MacDonald T, Priebe W, DeCuypere M, Heimberger AB. A First-in-Human Phase I Trial of the Oral p-STAT3 inhibitor WP1066 in Patients with Recurrent Malignant Glioma. CNS Oncology 11(2):CNS87, 2022. e-Pub 2022. PMID: 35575067.
Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Robell L, Majd N, de Groot J, Esquenazi Y, Kamiya-Matsuoka C, Ballester L. Molecular, Histologic and Clinical Characteristics of Oligodendrogliomas: A Multi-institutional Retrospective Study. Neurosurgery 90(5):515-522, 2022. e-Pub 2022. PMID: 35179134.
Muir M, Patel R, Traylor JI, Chaves de Almeida Bastos D, Kamiya-Matsuoka C, Li J, Rao G, Prabhu SS. Laser Interstitial Thermal Therapy for Newly Diagnosed Glioblastoma. Lasers Med Sci 37(3):1811-1820, 2022. e-Pub 2022. PMID: 34687390.
Bhat K, Gupta P, Dang M, Hao D, Tran T, Kamiya-Matsuoka C, Gumin J, Lang F, Navin N, Wang L. Single-cell transcriptomic and epigenomic immune landscape of human gliomas. S32 Brain Tumor Res Treat Supplement. e-Pub 2022.
Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SL. Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv 4(1):vdac129, 2022. e-Pub 2022. PMID: 36128585.
Rubino F, Schur S, McGovern S, Kamiya-Matsuoka C, DeMonte F, Raza S. Impact of Salvage Surgery and Re-irradiation for Radiation Failed Recurrent Skull Base Meningiomas. Open Works at MD Anderson, 2022. e-Pub 2022.
Traylor, JI, Patel, RP, Muir, M, de Almeida Bastos, DC, Ravikumar, V, Kamiya Matsuoka, C, Rao, G, Thomas, JG, Kew, Y, Prabhu, SS. Laser Interstitial Thermal Therapy for Glioblastoma. World Neurosurgery 149:e244-e252, 2021. e-Pub 2021. PMID: 33610872.
Khan B, Kamiya-Matsuoka C, Lee S, Rahman M, Rao G. Prolonged Survival After Laser Interstitial Thermal Therapy in Glioblastoma. Surg Neurol Int 12:228, 2021. e-Pub 2021. PMID: 34221559.
Sinning M, Frelinghuysen M, Gallegos M, Cordova A, Paredes P, Vogel C, Sujima E, Kamiya-Matsuoka C, Valdivia F. Outcome of patients with primary glioblastoma in Chile: Single center series. Ecancermedicalscience 15:1184, 2021. e-Pub 2021. PMID: 33777177.
Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A. Efficacy of Pembrolizumab in Patients with Pituitary Carcinoma: results from a phase II study. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33427689.
Nam JY, Gilbert A, Cachia D, Mandel J, Fuller GN, Penas-Prado M, de Groot J, Kamiya-Matsuoka C. Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. Neurooncol Pract 7(6):613-619, 2020. e-Pub 2020. PMID: 33312675.
Anakwenze CP, McGovern S, Taku N, Liao K, Boyce-Fappiano DR, Kamiya-Matsuoka C, Ghia A, Chung C, Trifiletti D, Ferguson SD, Li J, Yeboa DN. Association Between Facility Volume and Overall Survival for Patients with Grade II Meningioma after Gross Total Resection. World Neurosurg 141:e133-e144, 2020. e-Pub 2020. PMID: 32407910.
Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res 26(14):3565-3577, 2020. e-Pub 2020. PMID: 32299815.
de Groot J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, Pei B, O'Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22(4):539-549, 2020. e-Pub 2020. PMID: 31755915.
Kamiya-Matsuoka C, Hamza MA, de Groot JF. Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Neurosci 74:36-40, 2020. e-Pub 2020. PMID: 31982279.
Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma 60(13):3292-3295, 2019. e-Pub 2019. PMID: 31246142.
Majd N, Kamiya-Matsuoka C, de Groot JF. The path forward for anti-programed cell death-1 therapy in gliomas. Curr Opin Neurol 32(6):864-871, 2019. e-Pub 2019. PMID: 31567548.
Baig M, Fuller G, Gupta S, Tran G, Mork M, Slopis J, Kamiya C, Khatua S, Zaky W, Sadighi Z. Pdct-02. Unique concurrent association of somatic and germline nf1 mutations with germline mismatch repair mutations in pediatric glioblastoma multiforme. Neuro-Oncology 21(suppl 6):vi183, 2019. e-Pub 2019.
Santos-Pinheiro F, Penas-Prado M, Kamiya-Matsuoka C, Waguespack SG, Mahajan A, Brown PD, Shah KB, Fuller GN, McCutcheon IE. Treatment and long-term outcomes in pituitary carcinoma: a cohort study. Eur J Endocrinol 181(4):397-407, 2019. e-Pub 2019. PMID: 31349217.
Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer 112:83-93, 2019. e-Pub 2019. PMID: 30951926.
D’Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, Groot JD, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras CE, McCutcheon I, Nam D, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss DE, Kim S, Meyronet D, Mokhtari K, Salvador H, Bhat KP, Eoli M, Sanson M, Lasorella A, Iavarone A. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med 25(1):176-187, 2019. e-Pub 2019. PMID: 30531922.
Kassab C, Zamler D, Kamiya-Matsuoka C, Gatalica Z, Xiu J, Spetzler D, Heimberger AB. Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma. Clin Oncol Res 2(3):2-8, 2019. e-Pub 2019. PMID: 31712784.
Daher A, Kamiya-Matsuoka C, Loghin ME, Penas-Prado M, Tummala S. Neuromuscular weakness syndromes from immune checkpoint inhibitors: A case series and literature review. J Immunother Precis Oncol 2(3):93-100, 2019. e-Pub 2019.
Daher A, Kamiya-Matsuoka C, Woodman K. Patient With 2 Hematologic Malignancies Presenting as Neurolymphomatosis. J Clin Neuromuscul Dis 19(3):124-130, 2018. e-Pub 2018. PMID: 29465612.
Cachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, Colen R, de Groot JF. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. Journal of Neuro-Oncology 135(1):75-81, 2017. e-Pub 2017. PMID: 28702781.
Kamiya-Matsuoka C, Tummala S. Electrographic patterns in patients with posterior reversible encephalopathy syndrome and seizures. J Neurol Sci 375:294-298, 2017. e-Pub 2017. PMID: 28320152.
Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol 92(2):155-160, 2017. e-Pub 2017. PMID: 27874212.
Liao B, Kamiya-Matsuoka C, Fang X, Smith RG, Shanina E. Alternating Ptosis Associated with Asialo-GM1 and GD1b Antibodies. Int J Neurosci 126(12):1-9, 2016. e-Pub 2015. PMID: 26710925.
Kamiya-Matsuoka C, Cachia D, Waguespack SG, Crane CH, Mahajan A, Brown PD, Nam JY, McCutcheon IE, Penas-Prado M. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. Pituitary 19(4):415-21, 2016. e-Pub 2016. PMID: 27106209.
Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol 128(1):75-84, 2016. e-Pub 2016. PMID: 26900076.
Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 126(3):527-533, 2016. e-Pub 2015. PMID: 26566652.
Rizk N, Kamiya-Matsuoka C, Tremont-Lukats IW. Lower Extremity Edema, Anxiety, and Cyanosis During Chemoradiation Therapy for Glioblastoma. JAMA Oncol:1-3. e-Pub 2015. PMID: 26540389.
Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol 125(2):401-10, 2015. e-Pub 2015. PMID: 26354773.
Kamiya-Matsuoka C, Cachia D, Yust-Katz S, Rodriguez YA, Garciarena P, Rodarte EM, Tremont-Lukats IW. Ischemic stroke in patients with gliomas at The University of Texas-M.D. Anderson Cancer Center. J Neurooncol 125(1):143-8, 2015. e-Pub 2015. PMID: 26272599.
Bittar J, Kamiya-Matsuoka C, Barata PC, Lee-Kim SH, Olar A, Tremont-Lukats IW. Corticosteroid sensitivity in gliomatosis cerebri delays diagnosis. Pract Neurol 15(4):309-11, 2015. e-Pub 2015. PMID: 25922538.
Pachella LA, Kamiya-Matsuoka C, Lee EL, Olar A, Yung WK. Supratentorial extraventricular anaplastic ependymoma with extracranial metastasis. J Clin Neurosci 22(3):605-7, 2015. e-Pub 2015. PMID: 25455735.
Mella DB, Kamiya-Matsuoka C, Liao B, Tummala S, de Groot J. Recurrent encephaloclastic cyst induced by intraventricular topotecan. J Neurol Sci 349(1-2):52-3, 2015. e-Pub 2015. PMID: 25598491.
Liao B, Rodriguez RM, Metrus NR, Kamiya-Matsuoka C. Pseudoabducens palsy mimicking myasthenia gravis. BMJ Case Rep 2015, 2015. e-Pub 2015. PMID: 25733096.
Liao B, Kamiya-Matsuoka C. Atypical isolated nuclear oculomotor nerve syndrome: a diagnostic challenge. BMJ Case Rep 2015, 2015. e-Pub 2015. PMID: 25694634.
Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol 122(2):391-398, 2015. e-Pub 2015. PMID: 25666482.
Liao B, Kamiya-Matsuoka C, Fang X, Smith RG. Refractory IgG4-related intracranial hypertrophic pachymeningitis responded to rituximab. Neurol Neuroimmunol Neuroinflamm 1(4):e41, 2014. e-Pub 2014. PMID: 25364775.
Kamiya-Matsuoka C, Shroff S, Gildersleeve K, Hormozdi B, Manning JT, Woodman KH. Neurolymphomatosis: a case series of clinical manifestations, treatments, and outcomes. J Neurol Sci 343(1-2):144-8, 2014. e-Pub 2014. PMID: 24928074.
Liao B, Kamiya-Matsuoka C, Gong Y, Chen M, Wolf BA, Fowler NH. Primary natural killer/T-cell lymphoma presenting as leptomeningeal disease. J Neurol Sci 343(1-2):46-50, 2014. e-Pub 2014. PMID: 24880537.
Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589-93, 2014. e-Pub 2014. PMID: 24482447.
Kamiya-Matsuoka C, Blas-Boria D, Williams MD, Garciarena P, Tummala S, Tremont-Lukats IW. N-type calcium channel antibody-mediated paraneoplastic limbic encephalitis: a diagnostic challenge. J Neurol Sci 338(1-2):188-90, 2014. e-Pub 2014. PMID: 24462122.
Kamiya-Matsuoka C, Cachia D, Olar A, Armstrong TS, Gilbert MR. Primary brain tumors and posterior reversible encephalopathy syndrome. . Neuro Oncol Pract 1(4):184-190, 2014. e-Pub 2014. PMID: 26034631.
Kamiya-Matsuoka C, Shroff S, Tatsui CE, Tremont-Lukats IW, Gilbert MR. Sinking skin flap syndrome in glioblastoma. BMJ Case Rep 2014, 2014. e-Pub 2014. PMID: 25398923.
Kamiya Matsuoka, C, Garciarena, P, Amin, H, Tremont, I, de Groot, JF. B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy. Neurology: Clinical Practice 3(6):532-534, 2013. e-Pub 2013. PMID: 30107017.
Munoz J, Kumar VA, Hamilton J, Pasche LJ, Langford LA, Taggart MW, Kamiya-Matsuoka C, Tummala S, Moulder S, Kurzrock R. Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol 31(20):e360-3, 2013. e-Pub 2013. PMID: 23733774.
Kamiya-Matsuoka C, Garciarena P, Hesham AM, Tremont-Lukats IW, de Groot JF. B Lymphoblastic Leukemia/Lymphoma Presenting As Seventh Cranial Nerve Palsy. Neurol Clin Pract. Neurol Clin Pract 3(6):532-534, 2013. e-Pub 2013.

Invited Articles

Majd N, Kamiya-Matsuoka C, de Groot JF. The path forward for anti-programed cell death-1 therapy in gliomas. Curr Opin Neurol 32(6):864-871, 2019. e-Pub 2019. PMID: 31567548.
Kamiya-Matsuoka C, Gilbert MR. Treating recurrent glioblastoma: an update. CNS Oncol 4(2):91-104, 2015. e-Pub 2015. PMID: 25768333.

Review Articles

Lam, K, Kamiya Matsuoka, C, Slopis, JM, McCutcheon, IE, Majd, NK. Therapeutic Strategies for Gliomas Associated with Cancer Predisposition Syndromes. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 38394467.
Daher, A, Kamiya Matsuoka, C, Loghin, ME, Penas-Prado, M, Tummala, S. Neuromuscular weakness syndromes from immune checkpoint inhibitors. Journal of Immunotherapy and Precision Oncology 2(3):93-100, 2019. e-Pub 2019.
Yust Katz S, Cachia D, Kamiya-Matsuoka C, Olar A, Theeler B, Penas Prado M, Gilbert MR, Armstrong T. Ependymomas arising outside of the central nervous system: A case series and literature review. J Clin Neurosci 47:202-207, 2018. e-Pub 2018. PMID: 29054328.
Shroff S, Kamiya-Matsuoka C, Woodman K. An unusual cause of cerebellar ataxia in an immunocompromised elderly patient. J Neurol Sci 340(1-2):218-20, 2014. e-Pub 2014. PMID: 24635888.

Professional Educational Materials

Kamiya C. Standardized Protocol: Lumbar Puncture and/or Intrathecal Chemotherapy Administration, for APNs and PAs, MDACC, 2019.

Editorials

Inga E, Lopez G, Kamiya-Matsuoka C. Biological accidents in medical students of the National University of San Marcos: prevalence, mechanisms and risk factors. An Fac Med 71(1):37-42, 2010.

Abstracts

Garcia C, Lam K, Puduvalli V, Kamiya-Matsuoka C. Gliomas associated with Li-Fraumeni Syndrome. SNO 27(Suppl 5):v326, 2025. e-Pub 2025.
Lang FF, Shpall E, Weinbereg JS, Ene C, Chen S, Young C, Kamiya C, Fueyo J, Gomez-Manzano C, Peter K. TIP-21 Phase I trial of mesenchymal stem cells carrying Delta-24-RGD given intraarterially in recurrent glioma: Early report. SNO 27(Suppl 5):v425, 2025. e-Pub 2025.
Colman H, Lombardi G, Wong E, Walbert T, Eoli M, Lassman A, Peereboom D, Kizilbash S, Kamiya-Matsuoka C, Pitz M, Strowd R, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth P, Hamza M, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann E, Welsh L, Wen P, Dietrich J, Levin V. CTIN-58 Updated results of Phase 3 STELLAR trial: Eflornithine improves overall survival and blinded independent central review determined progression free survival in patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma. SNO 27(Suppl 5):v139-v140, 2025. e-Pub 2025.
Majd N, Dagher S, Wang S, Salvatierra M, Soto LS, Liu S, Yeboa N, Weathers S, Gachimova E, Wathoo C, Kamiya-Matsuoka C, O’Brien B, Patel A, Puduvalli V, Wintermark M, Yuan Y, Haymaker C, Raleigh DR, Groot JD. DNAR-08 Phase I Trial of Peposertib (DNA-PK inhibitor) Plus Radiation in Newly Diagnosed MGMT-Unmethylated Glioblastoma, Updated Clinical, Radiographic, and Biomarker Outcomes. SNO 27(Suppl 5):v152, 2025. e-Pub 2025.
Cutarella S, Puduvalli VK, Kamiya-Matsuoka C. BIOM-63 Molecular features of aggressive MMR deficiency brain tumors and response to immunotherapy. SNO 27(Suppl 5):v38, 2025. e-Pub 2025.
Patel AD, Aaroe A, Kamiya-Matsuoka C, Lin R, Majd N, O'Brien BJ, Patel CB, Weathers SP, Puduvalli VK. Dual Targeting of VEGF and PD-1: A phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma. JCO 43(16). e-Pub 2025.
Gupta P, Dang M, Oberai S, Migliozzi S, Trivedi R, Kumar G, Peshoff M, Milam N, Ahmed A, Bojja K, Tran TM, Gumin J, Kamiya-Matsuoka C, Huse J, Cox K, Li J, Shehwana H, Sheth SA, Saxon R, Baohua S, Parker Kerrigan B, Maheshwari A, Parra Cuentas ER, Navin NE, Heimberger AB, Lang FF, Iavarone A, Clise-Dwyer K, Wang L, Bhat KP. Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas 26(12):2239-2255, 2024. PMID: 39126294.
Brastianos P, Dooley K, Geyer S, Gerstner E, Kaufmann T, Iafrate A, Martinez-Lage M, Milhem M, Welch M, Kaley T, Drappatz J, Chan A, Kumthekar P, Matsuoka CK, Strowd R, Cohen A, Jaeckle K, Robell L, Magge R, Nam JY, Blondin N, Shaikh N, Rabinowitz I, Thomas A, Cahill D, Santagata S, Barker F, Galanis E. BIOM-12. ALLIANCE A071401: Genomically guided Phase II trial of abemaciclib in patients with Grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations. Neuro-Oncology 26(Supl 8):viii21. e-Pub 2024.
Kamiya-Matsuoka C, Weathers S, Harrison R, Majd N, Aaroe A, Knight S, Hanna T, Patel C, Langlands J, Brown D, Puduvalli V. CTNI-72. VAL-083 in patients with recurrent glioblastoma treated under expanded access program. Neuro-Oncology 26(Supl 8):viii113–viii114. e-Pub 2024.
Mohammed N, Patel C, Balar A, Buskirk SV, McGovern S, Raza S, DeMonte F, Ballester L, Youssef M, Kamiya-Matsuoka C. BIOM-68. Outcomes in patients with high-grade meningioma (HGM): A multi-institutional study. Neuro-Oncology 26(Supl 8):viii35–viii36. e-Pub 2024.
Kamiya-Matsuoka C, Patel C, Battiste J. INNV-34. Application of 200 KHz Tumor treating fields (TTFIELDS) in patients with infratentorial high-grade glioma: Case Series. Neuro-Oncology 26(Supl 8):viii176. e-Pub 2024.
Kamiya-Matsuoka C, Weathers S, Knight S, Hanna T, Langlands J, Brown D, Puduvalli V. CTNI-71. RELA fusion-positive ependymoma, diffuse midline glioma and grade 4 IDH mutant astrocytoma treated with VAL-083 under expanded access: Case reports. Neuro-Oncology 26(Supl 8):viii113. e-Pub 2024.
Kamiya Matsuoka C, Argao L, Yuan Y, Wall K, Kunst T, Chambers C, Vera E, Huguely C, Watanabe M, Grajkowska E, Abdullaev Z, Acquaye-Mallory A, Aldape K, Anderson B, Boris L, Bota DA, Briceno N, Burton E, Choi A, Cimino PJ, Giglio P, Kamiya-Matsuoka C, Kumthekar PU, Levine J, Lindhorst SM, Ozer B, Panzer M, Pillai T, Polskin L, Pratt D, Quezado M, Tweneboah-Koduah R, Wu J, Armstrong TS, Gilbert MR, Penas-Prado M. CTIM-03. Immune checkpoint inhibitor nivolumab in people with recurrent select rare CNS cancers: Results of interim analysis in a non-heavily pretreated cohort. Neuro-Oncology 26(8):viii85. e-Pub 2024.
Kamiya-Matsuoka C, Weathers S, Yung A, Login M, Majd N, Brown D, Langlands J, Schwartz R, Knight S, Puduvalli V, Groot JD, O’Brien B. CTNI-73. Assessment of molecular alterations in newly diagnosed GBM MGMT-unmethylated patients treated with VAL-083. Neuro-Oncology 26(Supl 8):viii114. e-Pub 2024.
Garcia C, Highsmith K, Knight S, Puduvalli V, Kamiya-Matsuoka C. NCOG-37. Single center experience of IDH inhibitors in the treatment of recurrent high grade gliomas. Neuro-Oncology 26(Supl 8):viii233. e-Pub 2024.
Majd N, Kamiya-Matsuoka C, Yuan Y, Gachimova E, Wathoo C, Dagher S, Chen M, McCutcheon I, Slopis J, Groot JD. CTNI-46. Window-Of-Opportunity trial of ulixertinib for MAPK-activated lower grade gliomas in adults. Neuro-Oncology 26(Supl 8):viii106–viii107. e-Pub 2024.
Majd N, Liu J, Yeboa N, Wang S, Weathers S, Yuan Y, Gachimova E, Wathoo C, Kamiya-Matsuoka C, O’Brien B, Aaroe A, Patel C, Patel A, Dagher S, Wintermark M, Ferguson S, Puduvalli V, Raleigh D, Groot JD. DNAR-10. Phase I clinical trial of peposertib plus radiotherapy in adults with newly-diagnosed MGMT-unmethylated glioblastoma. Neuro-Oncology 26(Supl 8):viii119. e-Pub 2024.
Colman H, Lombardi G, Wong E, Walbert T, Eoli M, Lassman A, Peereboom D, Kizilbash S, Kamiya-Matsuoka C, Pitz M, Strowd R, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth P, Hamza M, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann E, Welsh L, Wen P, Dietrich J, Levin V. Top-line results of STELLAR, a Phase 3 randomized trial of eflornithine and lomustine vs. lomustine for recurrent/progressive anaplastic astrocytoma. Neuro-Oncology 26(Supl 8):viii1. e-Pub 2024.
Colman H, Lombardi G, Wong E, Walbert T, Eoli M, Lassman A, Peereboom D, Kizilbash S, Kamiya-Matsuoka C, Pitz M, Strowd R, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth P, Hamza M, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann E, Welsh L, Wen P, Dietrich J, Levin V. Updated results of Phase 3 STELLAR study showing eflornithine improves overall survival (OS) and progression free survival (PFS) in patients with recurrent 2021 WHO grade 3 IDH-mutant astrocytoma. ICBTRT, 2024. e-Pub 2024.
Majd N, Kamiya-Matsuoka C, Yuan Y, Gachimova E, Wathoo C, Dagher S, Chen M, McCutcheon I, Slopis J, Groot JD. CTNI-46. Window-Of-Opportunity trial of ulixertinib for MAPK-activated lower grade gliomas in adults 26(Suppl 8):viii106-viii107, 2024. e-Pub 2024.
Garcia C, Highsmith K, Knight S, Puduvalli V, Kamiya-Matsuoka C. NCOG-37. Single center experience of IDH inhibitors in the treatment of recurrent high grade gliomas 26(Suppl 8):viii233, 2024. e-Pub 2024.
Mohammed N, Patel C, Balar A, Buskirk SV, McGovern S, Raza S, DeMonte F, Ballester L, Youssef M, Kamiya-Matsuoka C. BIOM-68. Outcomes in patients with high-grade meningioma (HGM): A multi-institutional study 26(Suppl 8):viii35-viii36, 2024. e-Pub 2024.
Kamiya-Matsuoka C, Weathers S, Yung A, Login M, Majd N, Brown D, Langlands J, Schwartz R, Knight S, Puduvalli V, Groot JD, O’Brien B. CTNI-73. Assessment of molecular alterations in newly diagnosed GBM MGMT-unmethylated patients treated with VAL-083. SNO 26(Suppl 8):viii114, 2024. e-Pub 2024.
Kamiya-Matsuoka C, Weathers S, Knight S, Hanna T, Langlands J, Brown D, Puduvalli V. CTNI-71. RELA fusion-positive ependymoma, diffuse midline glioma and grade 4 IDH mutant astrocytoma treated with VAL-083 under expanded access: Case reports. SNO 26(Suppl 8):viii113. e-Pub 2024.
Kamiya-Matsuoka C, Weathers S, Harrison R, Majd N, Aaroe A, Knight S, Hanna T, Patel C, Langlands J, Brown D, Puduvalli V. CTNI-72. VAL-083 in patients with recurrent glioblastoma treated under expanded access program. SNO 26(Suppl 8):viii113–viii114. e-Pub 2024.
Brastianos P, Dooley K, Geyer S, Gerstner E, Kaufmann T, Iafrate A, Martinez-Lage M, Milhem M, Welch M, Kaley T, Drappatz J, Chan A, Kumthekar P, Matsuoka CK, Strowd R, Cohen A, Jaeckle K, Robell L, Magge R, Nam JY, Blondin N, Shaikh N, Rabinowitz I, Thomas A, Cahill D, Santagata S, Barker F, Galanis E. BIOM-12. ALLIANCE A071401: Genomically guided Phase II trial of abemaciclib in patients with Grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations 26(Suppl 8):viii21, 2024. e-Pub 2024.
Kamiya-Matsuoka C, Weathers S, Harrison R, Majd N, Aaroe A, Knight S, Hanna T, Patel C, Langlands J, Brown D, Puduvalli V. CTNI-72. VAL-083 in patients with recurrent glioblastoma treated under expanded access program 26(Suppl 8):viii113-viii114, 2024. e-Pub 2024. PMID: 11553344.
Kamiya-Matsuoka C, Patel C, Battiste J. INNV-34. Application of 200 KHz Tumor treating fields (TTFIELDS) in patients with infratentorial high-grade glioma: Case Series 26(Suppl 8):viii176, 2024. e-Pub 2024.
Argao L, Yuan Y, Wall K, Kunst T, Chambers C, Vera E, Huguely C, Watanabe M, Grajkowska E, Abdullaev Z, Acquaye-Mallory A, Aldape K, Anderson B, Boris L, Bota DA, Briceno N, Burton E, Choi A, Cimino P, Giglio P, Kamiya-Matsuoka C, Kumthekar PU, Levine J, Lindhorst SM, Ozer B, Panzer M, Pillai T, Polskin L, Pratt D, Quezado M, Tweneboah-Koduah R, Wu J, Armstrong TS, Gilbert MR, Penas-Prado M. CTIM-03. Immune checkpoint inhibitor nivolumab in people with recurrent select rare CNS cancers: Results of interim analysis in a non-heavily pretreated cohort. SNO 26(Suppl 8):viii85, 2024. e-Pub 2024.
Sloan AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N, Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M, Mehta MP. NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma. Neuro-Oncology 26(9):1628–1637. e-Pub 2024.
Majd N, Yeboa D, Wang S, Weathers SS, Yuan Y, Anssari HA, Kamiya-Matsuoka C, O'Brien BJ, Aaroe A, Patel CB, Dagher S, Wintermark M, Ferguson SD, Puduvalli VK, Liu SJ, Raleigh DR, de Groot AJF. Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma. e-Pub 2024.
Brastianos PK, Dooley K, Geyer SM, Gerstner ER, Kaufmann TJ, Iafrate A, Milhem MM, Welch MR, Kaley TJ, Drappatz J, Chan A, Kumthekar P, Kamiya-Matsuoka C, Strowd RE, Cohen AL, Jaeckle KA, Robell L, Santagata S, Frederick G Barker II, Galanis E. Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations. ASCO 42(16 Suppl). e-Pub 2024.
Majd N, Yeboa D, Wang S, Weathers SS, Yuan Y, Anssari HA, Kamiya-Matsuoka C, O'Brien BJ, Aaroe A, Patel CB, Dagher S, Wintermark M, Ferguson SD, Puduvalli VK, Liu SJ, Raleigh DR, de Groot AJF. DNAR-10. Phase I clinical trial of peposertib plus radiotherapy in adults with newly-diagnosed MGMT-unmethylated glioblastoma. ASCO 42(16 Suppl). e-Pub 2024.
Garcia CR, Highsmith KN, Knight S, Puduvalli VK, Kamiya-Matsuoka AC. Single center experience of IDH inhibitors in the treatment of recurrent high grade gliomas. JCO 42(Supl 16). e-Pub 2024.
Brastianos PK, Dooley K, Geyer SM, Gerstner ER, Kaufmann TJ, Iafrate A, Milhem MM, Welch MR, Kaley TJ, Drappatz J, Chan A, Kumthekar P, Kamiya-Matsuoka C, Strowd RE, Cohen AL, Jaeckle KA, Robell L, Santagata S, Frederick G Barker II, Galanis E. Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations. JCO 42(Supl 16). e-Pub 2024.
Garcia C, Knight S, Puduvalli V, Kamiya-Matsuoka AC. Long-term Survival in a WHO Grade 4 IDH-mutant Astrocytoma Using a Farnesyltransferase Inhibitor in Combination with Temozolomide (P4-5.006). Neurology 102(7 supl 1). e-Pub 2024.
Garcia C, Knight S, Puduvalli V, Kamiya-Matsuoka AC. Long-term Survival in a WHO Grade 4 IDH-mutant Astrocytoma Using a Farnesyltransferase Inhibitor in Combination with Temozolomide (P4-5.006) 102(Suppl 7):7011. e-Pub 2024.
Kamiya Matsuoka C, Yeboa D, Weathers S, Yuan Y, Robichaux C, Anssari HA, Gachimova E, Loghin M, Kamiya-Matsuoka C, O'Brien B, Aaroe A, Patel C, Yung W, Wintermark M, Gule M, Ferguson S, Puduvalli V, Groot JD. CTNI-42. Phase I clinical trial of peposertib plus radiation in newly diagnosed MGMT-unmethylated glioblastoma. Neuro-Oncology 25(Supl 5):v84. e-Pub 2023.
Patel A, Whitfield B, Ballester L, Puduvalli V, Kamiya-Matsuoka C. CTNI-46. Upfront versus deferred treatment in lower grade IDH-mutant gliomas: A single-center retrospective analysis. Neuro-Oncology 25(Supl 5):v85. e-Pub 2023.
Lam K, Kamiya-Matsuoka C. BIOM-47. Clinical and molecular features of patients with Li-Fraumeni syndrome and glioma: An MD Anderson Cancer Center Experience. Neuro-Oncology 25(Supl 5):v15. e-Pub 2023.
Weathers S, Kamiya-Matsuoka C, Majd N, Ashu A, Thompson C, Gachimova E, Aaroe A, Patel C, Loghin M, O'Brien B, Yung W, Puduvalli V, Groot JD. CTIM-23 - Safety run-in results of a phase I/II study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma. Neuro-Oncology 25(Supl 5):v67. e-Pub 2023.
Majd N, Yeboa D, Weathers S, Yuan Y, Robichaux C, Anssari HA, Gachimova E, Loghin M, Kamiya-Matsuoka C, O'Brien B, Aaroe A, Patel C, Yung W, Wintermark M, Gule M, Ferguson S, Puduvalli V, Groot JD. CTNI-42. Phase I clinical trial of peposertib plus radiation in newly diagnosed MGMT-unmethylated glioblastoma 25(Suppl 5):v84, 2023. e-Pub 2023.
Weathers S, Kamiya-Matsuoka C, Majd N, Ashu A, Thompson C, Gachimova E, Aaroe A, Patel C, Loghin M, O'Brien B, Yung W, Puduvalli V, Groot JD. CTIM-23 - Safety run-in results of a phase I/II study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma 25(Suppl 5):v67, 2023. e-Pub 2023.
Kamiya-Matsuoka C, Weathers S, Yung W, Loghin M, Majd N, Brown D, Langlands J, Schwartz R, Knight S, Puduvalli V, Groot JD, O'Brien B. CTNI-78. Evaluation of post-progression treatments after VAL-083 in recurrent and newly diagnosed GBM MGMT-unmethylated patients 25(Suppl 5):v95-v96, 2023. e-Pub 2023.
Patel A, Whitfield B, Ballester L, Puduvalli V, Kamiya-Matsuoka C. CTNI-46. Upfront versus deferred treatment in lower grade IDH-mutant gliomas: A single-center retrospective analysis 25(Suppl 5):v85, 2023. e-Pub 2023.
Lam K, Kamiya-Matsuoka C. BIOM-47. Clinical and molecular features of patients with Li-Fraumeni syndrome and glioma: An MD Anderson Cancer Center Experience 25(Suppl 5):v15, 2023. e-Pub 2023.
Schrank BR, Manzar GS, Wu SY, Gunther JR, Fang P, Jabbour EJ, Lim TY, Daver NG, Cykowski MD, Fuller GN, Cachia D, Kamiya-Matsuoka C, Woodman KH, DiNardo CD, Jain N, Short NJ, Sasaki K, Dabaja B, Kantarjian HM, Pinnix CC. Dorsal Column Myelopathy Following Intrathecal Chemotherapy for Leukemia. International Journal of Radiation Oncology*Biology*Physics 117(2):e486-e487. e-Pub 2023.
Gregory T, Knight S, Aaroe A, O'Brien BJ, Patel CB, Weathers SS, Majd N, Puduvalli VK, Kamiya-Matsuoka C. Accelerated tumor progression among glioma patients after COVID-19 infection. J Clin Oncol 41(suppl 16), 2023. e-Pub 2023.
Gupta P, Dang M, Oberai S, Peshoff M, Milam N, Ahmed A, Bojja K, Tran TM, Cox K, Shehwana H, Matsuoka CK, Li J, Gumin J, Goldman A, Seth SA, Maheshwari A, Lang FF, Navin NE, Heimberger AB, Dwyer KC, Wang L, Bhat KP. Immunophenotyping of human brain tumors reveals myeloid cell mediated anti-glioma axis. Cancer Res 83(7 Supl):669. e-Pub 2023.
Gupta P, Dang M, Oberai S, Peshoff M, Milam N, Ahmed A, Bojja K, Tran TM, Cox K, Shehwana H, Kamiya Matsuoka C, Li J, Gumin J, Goldman A, Seth SA, Maheshwari A, Lang FF, Navin NE, Heimberger AB, Dwyer KC, Wang L, Bhat KP. Immunophenotyping of human brain tumors reveals myeloid cell mediated anti-glioma axis. Cancer Res 83(7 suppl):669, 2023. e-Pub 2023.
Kamiya-Matsuoka C, Weathers SP, Harrison RA, Majd NK, Aaroe AE, Knight S, Hanna T, Gregory TA, Langlands J, Brown D, Puduvalli VK. VAL-083 in patients with recurrent glioblastoma treated under expanded access program. Cancer Res 83(8 suppl):LB127, 2023. e-Pub 2023.
Kamiya-Matsuoka C, Knight S, Hanna T, Gregory TA, Langlands J, Brown D, Puduvalli VK. RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports [abstract]. Cancer Res 83(8 suppl):LB126, 2023. e-Pub 2023.
Yap TA, Daveer N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F. Highlights from Recent Cancer Literature: Trial Results with OXPHOS Inhibitors. Cancer Res 83(6):805-806, 2023. e-Pub 2023.
Gupta P, Dang M, Hao D, Bojja K, Tran T, Shehwana H, Kamiya-Matsuoka C, Li J, Audia A, Kassab C, Ott M, Gumin J, Alenazy S, Goldman A, Seth S, Maheshwari A, Balasubramaniyan V, Vaillant B, de Groot J, Lavarone A, Lang F, Navin N, Heimberger A, Wang L, Bhat K. Immunophenotyping of brain tumors identifies interferon enriched phagocytes in human gliomas. Journal for ImmunoTherapy of Cancer, 2022. e-Pub 2022.
Kamiya-Matsuoka C, Majd N, Harrison R, Knight S, Langlands J, Brown D, Puduvalli V. VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program. Neuro-Oncology 24(suppl 7):vii107, 2022. e-Pub 2022.
Kamiya-Matsuoka C, Knight S, Langlands J, Brown D, Puduvalli V. Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access. Neuro-Oncology 24(suppl 7):vii106, 2022. e-Pub 2022.
Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Robell L, Majd NK, de Groot JF, Esquenazi Y, c K, Ballester LY. Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. Neurosurgery 90(5):515-522, 2022. e-Pub 2022. PMID: 35179134.
Bhat K, Gupta P, Dang M, Hao D, Tran T, Kamiya-Matsuoka C, Gumin J, Lang F, Navin N, Wang L. Single-cell transcriptomic and epigenomic immune landscape of human gliomas. S32 Brain Tumor Res Treat Supplement. e-Pub 2022.
Upadhyay R, Khose S, Pokhylevych H, dela Cruz Paulino A, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, DeGroot J, Puduvalli V, Tatsui C, Prabhu S, Zaky W, Lin F, Weinberg J, Rhines L, Fuller G, Sandberg D, Johnson JM, McGovern S. Role of Radiotherapy in Management of Primary Spinal High Grade Glioma: A single institution retrospective analysis. Neuro Oncology 23(Suppl 6):vi42-vi43, 2021. e-Pub 2021.
Weathers SP, Knafl M, Parra E, Hernandez S, Solis L, Sanchez Espiridion B, Wistuba I, Futreal A, Maru D, Kamiya-Matsuoka C, Harrison R, Joseph V, Yun C, Darbonne W, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien B, Woodman S, DeGroot J. Biomarker immune correlates in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation. Neuro Oncology 23(Suppl 6):vi49, 2021. e-Pub 2021.
Ou A, Lin H, Yuan Y, Bornstein C, Alfaro-Munoz K, Afshar-Kharghan V, Kamiya-Matsuoka C, Majd N. Risk and burden of thromboembolic and hemorrhagic events in patients with malignant glioma receiving bevacizumab. Neuro Oncology 23(Suppl 6):vi148, 2021. e-Pub 2021.
Ludford K, Singh Raghav KP, Blum Murphy MA, Fleming ND, Nelson DA, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar Sanchez E, Dasari A, Thomas JV, Foo WC, Qiao W, Kopetz S, Overman MJ. Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency. Annals of Oncology 32(Suppl 5):S1210, 2021. e-Pub 2021.
Gupta P, Dang M, Hao D, Bojja K, Tran TM, Shehwana H, Kamiya-Matsuoka C, Li J, Audia A, Kassab C, Ott M, Gumin J, Alenazy S, Goldman A, Seth SA, Maheshwari A, Balasubramaniyan V, Vaillant B, de Groot JF, Lang FF, Iavarone A, Navin NE, Heimberger AB, Wang L, Bhat KP. OTME-23. Single-cell transcriptomic and epigenomic immune landscape of isocitrate dehydrogenase stratified human gliomas. Neurooncol Adv 3(Suppl 2):ii18, 2021. e-Pub 2021.
Gupta P, Dang M, Hao D, Bojja K, Tran TM, Shehwana H, Kamiya-Matsuoka C, Li J, Audia A, Kassab C, Ott M, Gumin J, Alenazy S, Goldman A, Seth SA, Maheshwari A, Balasubramaniyan V, Vaillant B, de Groot JF, Lang FF, Iavarone A, Navin NE, Heimberger AB, Wang L, KP B. OTME-23. Single-cell transcriptomic and epigenomic immune landscape of isocitrate dehydrogenase stratified human gliomas. Neurooncol Advances V3(Suppl 2), 2021. e-Pub 2021.
Gupta P, Dang M, Hao D, Bojja K, Tran TM, Shehwana H, Kamiya-Matsuoka C, Li J, Audia A, Kassab C, Ott M, Gumin J, Alenazy S, Goldman A, Seth SA, Maheshwari A, Balasubramaniyan V, Vaillant B, de Groot JF, Lang FF, Iavarone A, Navin NE, Heimberger AB, Wang L, Bhat KP. Single-cell transcriptomic and epigenomic immune landscape of human gliomas 3(Suppl 2):ii18, 2021. e-Pub 2021.
Ludford K, Singh Raghav KP, Blum Murphy MA, Fleming ND, Nelson DA, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar Sanchez E, Dasari A, Thomas JV, Foo WC, Qiao W, Kopetz S, Overman MJ. Safety and Efficacy of Neoadjuvant Pembrolizumab in Mismatch Repair Deficient Localized/Locally Advanced Solid Tumors. Journal of Clinical Oncology 39(Suppl 15):2520, 2021. e-Pub 2021.
O'Brien B, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Knight S, Yuan Y, Bacha J, Brown D, Steino A, Johnson G, Kanekal S, Langlands J, Lopez L, Schwartz R, Penas-Prado M, DeGroot J. Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Caner Research 81(Suppl 13):CT238, 2021. e-Pub 2021.
O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Knight S, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, DeGroot J. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro Oncology 23(Suppl 6):vi65, 2021. e-Pub 2021.
Aaroe A, Dono A, Youssef M, Alfaro-Munoz K, Weathers SP, O’Brien B, Majd N, Harrison R, Loghin M, Soomro Z, Williford G, Fuller G, Yung WKA, Yeboa D, Esquenazi Y, Ballester LY, de Groot J, Kamiya-Matsuoka C. A retrospective study of treatment strategies and outcomes in WHO grade II and III isocitrate dehydrogenase (IDH) wild-type astrocytoma. Neuro Oncol 22(Suppl):ii164-ii165, 2020. e-Pub 2020.
Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia C, Soomro Z, Williford G, Takayasu T, Robell L, Majd N, de Groot J, Esquenazi Y, Kamiya-Matsuoka C, Ballester LY. Molecular, histologic and clinical characteristics of oligodendrogliomas: A multi-institutional retrospective study. Neuro Oncol 22(Suppl 2):ii168, 2020. e-Pub 2020.
Aaroe A, Team D, Harrison R, Majd N, O’Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WKA, de Groot J, Woodman K. A Snapshot of the impact of COVID-19 on patient with nervous system tumors. Neuro Oncol 22(Suppl 2):ii27, 2020. e-Pub 2020.
Youssef M, Pham L, Demirhan M, Harrison R, Loghin M, Johnson J, Alfaro-Munoz K, Bhat K, Yeboa D, Prabhu S, Raza S, de Groot J, Demonte F, Kamiya-Matsuoka C. Long-Term Use Of Everolimus Plus Octreotide For Recurrent Intracranial Or Spinal Meningioma: A Single Institution Experience. Neuro Oncol 22(Suppl 2):ii55, 2020. e-Pub 2020.
Gupta P, Dang M, Bojja K, Tran T, Shehwana H, Kamiya-Matsuoka C, Li J, Kassab C, Ott M, Gumin J, Maheshwari A, de Groot J, Lang F, Balasubramaniyan V, Navin N, Heimberger A, Wang L, Bhat K. Transcriptionally defined immune contexture in human gliomas at single-cell resolution. Neuro Oncology 22(Suppl 2):ii112, 2020. e-Pub 2020.
Gupta P, Dang M, Bojja K, Tran T, Shehwana H, Kamiya-Matsuoka C, Li J, Kassab C, Ott M, Gumin J, Maheshwari A, de Groot J, Lang F, Balasubramaniyan V, Navin N, Heimberger A, Wang L, Bhat K. Transcriptionally defined immune contexture in human gliomas at single-cell resolution. Neuro-Oncology Advances 22(suppl 2):ii112, 2020. e-Pub 2020.
O’Brien B, de Groot JF, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, Penas-Prado M. Phase II Study of Dianhydrogalactitol (VAL-083) in Patients with Bevacizumab-Naïve Recurrent Glioblastoma, MGMT-Unmethylated. Cancer Research 80(16 Suppl), 2020. e-Pub 2020.
Kamiya-Matsuoka C, Hamza MA, de Groot JF. Impact of adverse effects of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Neurosci 74:36-40, 2020. e-Pub 2020. PMID: 31982279.
O’Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Majd N, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, de Groot J. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-Unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro Oncol 22(2):ii59, 2020. e-Pub 2020.
Majd N, Waguespack S, Filip J, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza S, McCutcheon I, Aung N. Efficacy of pembrolizumab in patients with pituitary carcinoma: Results from a Phase II study. Neuro Oncology 22(suppl 2), 2020. e-Pub 2020.
Weathers SP, Penas-Prado M, Banerjee PP, Bdiwi M, Shaim H, Alsuliman A, Shanley M, Long J, de Groot JF, O'Brien BJ, Majd N, Harrison RA, Kamiya-Matsuoka C, Fuller GN, Chi L, Rao G, Lang FF, Shpall EJ, Rezvani, K, Heimberger AB. A Phase I/II Clinical Trial of Autologous CMV-Specific T cells in Glioblastoma (GBM) Patients Reveals a Lack of Immune Effector Function. Journal of Clinical Oncology 38(Suppl 15), 2020. e-Pub 2020.
Weathers SP, Kamiya-Matsuoka C, Harrison R, Liu D, Sanqui E, Dervin S, Yun C, Loghin M, Penas-Prado M, Majd N, Yung WKA, O’Brien B, de Groot J. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (ATEZO) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Neuro Oncology 22(Suppl 2):ii35, 2020. e-Pub 2020.
Weathers SP, Kamiya-Matsuoka C, Harrison RA, Liu DD, Dervin S, Yun C, Loghin ME, Penas-Prado M, Majd N, Yung WKA, O'Brien BJ, de Groot JF. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology 38(Suppl 15), 2020. e-Pub 2020.
Kassab C, Zamler D, Kamiya-Matsuoka C, Gatalica Z, Xiu J, Spetzler D, Heimberger A. Genetic and Immune Profiling for Potential Therapeutic Targets in Adult Human Craniopharyngioma. Clin Oncol Res 2(3):2-8, 2019. e-Pub 2019. PMID: 31712784.
Baig M, Fuller G, Gupta S, Tran G, Mork M, Slopis J, Kamiya-Matsuoka C, Khatua S, Zaky W, Sadighi Z. Unique concurrent association of somatic and germline NF1 mutations with germline mismatch repair mutations in pediatric glioblastoma multiforme. Neuro Oncol 21(Suppl 6):vi183, 2019. e-Pub 2019.
Metrus N, Kamiya-Matsuoka C, Weathers SP, Seligman C, O’Brien B. Improvement of Leptomeningeal Disease Following Infectious Meningitis. Neuro Oncology 21(Suppl 6):vi59, 2019. e-Pub 2019.
Kamiya-Matsuoka C, Metrus N, Weathers S, Ross J, Shaw KR, Penas-Prado M, Loghin ME, Alfaro-Munoz K, O'Brien BJ, Harrison R, Sadighi Z, Majd N, Yung WK, Meric-Bernstam F, Hambardzumyan D, de Groot J. Is Immuno-Oncology Therapy Effective in Hypermutator Glioblastomas with Somatic or Germline mutations. Annals of Oncology 30(Suppl 5):V144, 2019. e-Pub 2019.
Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot JF, O’Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Neuro Oncology Advances 1(Suppl 1):i8, 2019. e-Pub 2019.
Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot JF, O’Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Brain Metastasis research symposium, 2019. e-Pub 2019.
O’Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, de Groot JF. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Neuro Oncology 21(6):vi14-vi15, 2019. e-Pub 2019.
Trevino CR, Murthy RK, Raghavendra AS, Loghin M, Seligman C, Ferguson S, Kamiya-Matsuoka C, Harrison R, Sinicrope KD, Valero V, Tummala S, Hess K, Tripathy D, de Groot JF, O’Brien B. Intrathecal Trastuzumab plus/minus IT Topotecan for Patients with HER2+ Breast Cancer and Leptomeningeal Metastasis. Neuro-Oncology Advances(Suppl 1):i7-i8, 2019. e-Pub 2019.
Seligman C, Lee EL, Tummala S, Kamiya-Matsuoka C. Gram positive colonization of the Ommaya reservoir; treatment recommendations with clinical examples. Neuro Oncol 20(Suppl 6):vi146-vi147, 2018. e-Pub 2018.
Weathers SP, Kamiya-Matsuoka C, Dervin S, Yun C, Loghin M, O’Brien B, Harrison R, Yung WKA, Penas-Prado M, de Groot J. Safety run-in results of a phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Neuro Oncol 20(suppl 6):vi9-vi-10, 2018. e-Pub 2018.
de Groot JF, Penas-Prado M, Mandel J, O’Brien B, Weathers SP, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse JT, Rao G, Weinberg J, Prabhu S, Ferguson S, Yuan Y, Vence L, Allison J, Sharma P, Heimberger. A Window-of-opportunity clinical trial of pembrolizumab in recurrent glioblastoma patients. Neuron Oncology 20(Suppl 6):vi2, 2018. e-Pub 2018.
Metrus NR, Daher A, Harrison RA, Majd N, Maraka S, Nam JY, Trevino C, Weathers SP, O’Brien B, Kamiya-Matsuoka C, Loghin M, Alfaro K, Hunter K, Yung WKA, de Groot J, Penas-Prado M. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Neuro Oncology 20(Suppl 6):vi141, 2018. e-Pub 2018.
Hassan I, Kotrotsou A, Kamiya-Matsuoka C, Alfaro-Munoz KD, Elshafeey N, El Shafei N, Zinn P, de Groot JF, Colen R. A radiomic-based MRI phenotype is uniquely associated with hypermutated genotype in gliomas. Cancer Research 78(13 Suppl):2955, 2018. e-Pub 2018.
Johnson J, Metrus N, Kamiya-Matsuoka C. Glioblastoma that Arises from Tumefactive Multiple Sclerosis. Neurology 90(15 Suppl), 2018. e-Pub 2018.
Santos-Pinheiro F, Gatson NT, Kamiya-Matsuoka C, Fuller G, Weinberg J, Tremont I, de Groot JF, Loghin ME. Gliomatosis Cerebri: Predispositions and Predictors of Behavior. Neurology 90(15 Suppl), 2018. e-Pub 2018.
Zinn PO, Hassan I, Kotrotsou A, Kamiya-Matsuoka C, Alfaro-Munoz K, Elshafeey N, Elshafeey N, de Groot JF, Colen RR. Magnetic Resonance Imaging Vector Machine Learning Predicts the Glioma Hypermutation Phenotype. Congress of Neurological Surgeons, 2018. e-Pub 2018.
Penas-Prado M, Weathers SP, Zhou S, Kamiya-Matsuoka C, O’Brien B, Loghin M, Harrison R, Pei BL, Ictech S, Hunter K, Yung WKA, de Groot J, Shpall EJ, Heimberger A, Rezvani K. A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells (CMV-TC) for Glioblastoma: Dose Escalation and Correlative Results. Neuro Oncol 20(Suppl 6):vi2-vi3, 2018. e-Pub 2018.
Penas-Prado M, Rezvani K, Weathers SP, Zhou S, Kamiya-Matsuoka C, O'Brien BJ, Loghin ME, Harrison RA, Pei BL, Ictech S, Hunter K, Yung WKA, de Groot JF, Shpall EJ, Heimberger AB. A phase I/II clinical trial of autologous CMV-specific cytotoxic T cells (CMV-TC) for glioblastoma: Dose escalation results. Journal of Clinical Oncology 36(Suppl 15), 2018. e-Pub 2018.
Metrus N, Kamiya-Matsuoka C, Johnson J. Paroxysmal Singultus as the result of Brainstem Histoplasmosis. Neurology 90(15):Suppl 5.128, 2018. e-Pub 2018.
Hassan I, Kotrotsou A, Kamiya-Matsuoka C, Alfaro-Munoz KD, Elshafeey N, El Shafei N, Zinn P, de Groot JF, Colen R. A unique MRI-based radiomic signature predicts hypermutated glioma genotype. Journal of Clinical Oncology 36(Supple 15), 2018. e-Pub 2018.
O’Brien B, de Groot JF, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, Penas-Prado M. Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with MGMT-Unmethylated, Bevacizumab-Naïve Recurrent Glioblastoma. Neuro-Oncology 20(Suppl 6):vi17, 2018. e-Pub 2018.
O’Brien B, de Groot JF, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, Penas-Prado M. Phase II Study of Dianhydrogalactitol (VAL-083) in Patients with Bevacizumab-Naïve Recurrent Glioblastoma, MGMT-Unmethylated. Cancer Res 78(Suppl 13), 2018. e-Pub 2018.
Kamiya-Matsuoka C, Shaw K, Loghin ME, Penas-Prado M, O’Brien BJ, Weathers SP, Alfaro-Munoz KD, Yung WKA, de Groot JF. The Natural Course of Hypermutator Gliomas. Journal of Clinical Oncology 36(Suppl 15), 2018. e-Pub 2018.
Hassan I, Kotrotsou A, Kamiya-Matsuoka C, Alfaro-Munoz KD, Elshafeey N, Zinn P, de Groot JF, Colen R. Increased mutation burden (Hypermutation) in gliomas is associated with a unique radiomic texture signature in magnetic resonance imaging. Neuro Oncol 19(Suppl 6):vi147-vi148, 2017. e-Pub 2017.
Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal column myelopathy following intrathecal chemotherapy for leukemia. Am J Hematol 92(2):155-160, 2017. e-Pub 2017. PMID: 27874212.
Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Dave N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy Following Intrathecal Chemotherapy for Leukemia 92(2):155-160, 2017. e-Pub 2017. PMID: 27874212.
Kamiya-Matsuoka C, Shaw K, Loghin ME, Penas-Prado M, O’Brien BJ, Weathers SP, Alfaro-Munoz KD, Yung WKA, de Groot JF. The Natural Course of Hypermutator Gliomas. Neuro Oncol 19(6):vi179, 2017. e-Pub 2017.
Santos-Pinheiro F, Penas-Prado M, McCutcheon I, Waguespack S, Mahajan A, Brown P, Kamiya-Matsuoka C. Pituitary carcinoma: The University of Texas MD Anderson Cancer Center experience. Journal of Clinical Oncology 35(suppl 15), 2017. e-Pub 2017.
Nam J, Harrison RA, Weathers SP, Pillainayagam C, de Groot JF, Kamiya-Matsuoka C, Loghin ME, Penas-Prado M, Yung WKA, Li J, Ferguson SD, O'Brien BJ. Association of clinical phenotype and treatment history with survival in adult brainstem glioblastoma. Journal of Clinical Oncology 35(Suppl 15), 2017. e-Pub 2017.
Yust-Katz S, Cachia D, Kamiya-Matsuoka C, Theeler BJ, Olar A, Penas-Prado M, Armstrong T, Gilbert M. Ependymomas arising outside of the central nervous system: A case series. Neuro-Oncology 18(Suppl 6):vi162, 2016. e-Pub 2016.
Gatson NN, Kamiya-Matsuoka C, Rodriguez-Linares Y, Pillainayagam C, Cachia D, Daher A, Chi T, Weinberg J, Tremont-Lukats IW, Fuller G, de Groot JF, Loghin M. Rare-26. Gliomatosis, to be or not to cerebri: an evaluation of host systemic immune factors that potentially predispose to diffuse infiltrative glioma patterns. Neuro-Oncolgy 18(Suppl 6):vi165, 2016. e-Pub 2016.
Daher A, Johnson JK, Kamiya-Matsuoka C, Thomas S, Woodman K. Neurolymphomatosis and Anti-MAG Mononeuritis Multiplex in a Patient with Two Hematologic Malignancies. Neurology 86(16 Suppl):p6-284, 2016. e-Pub 2016.
Liao B, Kamiya-Matsuoka C, Smith RG, Ju H, Shanina E. Carpal Tunnel Syndrome Assessment in Elderly Patients - Problems and Potential Solutions, 2015. e-Pub 2015.
Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol 122(2):391-8, 2015. e-Pub 2015. PMID: 25666482.
Liao B, Kamiya-Matsuoka C. Atypical isolated nuclear oculomotor nerve syndrome: A diagnostic challenge. BMJ Case Rep, 2015. e-Pub 2015. PMID: 25694634.
Cachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, Colen R, de Groot JF. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients 17(5):v154, 2015. e-Pub 2015.
Shah R, Kamiya-Matsuoka C, Liao B, Tummala S. Electrographic Patterns In Patients With Posterior Reversible Encephalopathy Syndrome (PRES) And Seizures 84(14):Supplement P2.088, 2015. e-Pub 2015.
Kamiya-Matsuoka C, Liao B. Atypical isolated nuclear oculomotor nerve syndrome: A diagnostic challenge 84(14):Supplement P1.031, 2015. e-Pub 2015.
Barata PC, Kamiya-Matsuoka C, Lee-Kim SH, Loghin ME, O’Brien BJ, Tremont-Lukats IW. Outcomes after hospitalization in patients with recurrent glioblastoma 33:5s Supplement e13020, 2015. e-Pub 2015.
Mella DB, Kamiya-Matsuoka C, Liao B, Tummala S, de Groot JF. Encephaloclastic cyst induced by intraventricular topotecan 84(14):Supplement P3.138, 2015. e-Pub 2015.
Rengifo-Cam W, Kamiya-Matsuoka C, Nayfe R, Masaki T, Samadder J, Berstein E. Expression of Csk is associated with its methylation status in colorectal cancer cells 148(4):S-181, Supplement 1, 2015. e-Pub 2015.
Kamiya-Matsuoka C, Cachia D, Olar A, Armstrong TS, Gilbert MR. Primary brain tumors and posterior reversible encephalopathy syndrome. Neurooncol Pract 1(4):184-190, 2014. e-Pub 2014. PMID: 26034631.
Kamiya-Matsuoka C, Cachia D, Waguespack SG, McCutcheon IE, Mahajan A, Brown PD, Groves MD, Penas-Prado M. Temozolomide-based therapy for the management of progressive pituitary carcinoma. Neuro Oncol 16(suppl 5):v129, 2014. e-Pub 2014.
Liao B, Kamiya-Matsuoka C, Fang X, Smith GR. Refractory IgG4-related intracranial hypertrophic pachymeningitis. Neurol Neuroimmunol Neuroinflamm 1(4):e41, 2014. e-Pub 2014. PMID: 25364775.
Liao B, Kamiya-Matsuoka C, Fang X, Smith GR. Refractory IgG4-related intracranial hypertrophic pachymeningitis. Neurology 82(10), 2014. e-Pub 2014.
Kamiya-Matsuoka C, Cachia D, Armstrong TS, Gilbert MR. Primary Brain Tumors and Posterior Reversible Encephalopathy Syndrome 16(5):v26-v50, 2014. e-Pub 2014.
Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K. Myelopathy following intrathecal chemotherapy: a case series in adults 16(5):v26-v50, 2014. e-Pub 2014.
Kamiya-Matsuoka C, Liao B, Gong Y, Tremont-Lukats IW. Primary Natural Killer/T-cell Lymphoma Presenting as Leptomeningeal Disease. EFNS European Journal of Neurology 21(1):104-387, 2014. e-Pub 2014.
Kamiya-Matsuoka C, Cachia D, Waguespack SG, McCutcheon IE, Mahajan A, Brown PD, Groves MD, Penas-Prado M. Temozolomide-based therapy for the management of progressive pituitary carcinoma 16(5):v129, 2014. e-Pub 2014.
Hamza MA, Kamiya-Matsuoka C, de Groot JF. Impact of adverse effects of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Oncol 32(Suppl 2075):5, 2014. e-Pub 2014.
Kamiya-Matsuoka C, Liao B, Gong Y, Chen M, Woodman K, Fowler N, Conrad C. Primary Natural Killer/T-cell Lymphoma Presenting as Leptomeningeal Disease. Neurology 82(10):Supplement P7.029, 2014. e-Pub 2014.
Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical Neurological Complications of Ipilimumab Therapy in Patients with Metastatic Melanoma. Neurology 82(10 Suppl):P3-308, 2014. e-Pub 2014.
Kamiya-Matsuoka C, Liao B, Gong Y, Chen M, Woodman K, Fowler N, Conrad C. Primary Natural Killer/T-cell Lymphoma Presenting as Leptomeningeal Disease. Neurology 82(Suupl 10):260, 2014. e-Pub 2014.
Garciarena P, Kamiya-Matsuoka C, Tremont IW, Amin HM, de Groot JF. B lymphoblastic leukemia/lymphoma presenting as fifth and seventh cranial nerve palsy 80(1):Supplement P7.008, 2013. e-Pub 2013.
Paker AM, Kamiya-Matsuoka C, Chi L, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients 78(1):Supplement P6.015, 2012. e-Pub 2012.
Hormozdi B, Kamiya-Matsuoka C, Gildersleeve K, Woodman K. Neurolymphomatosis: A case series of clinical manifestations, treatments, and outcomes 78(1):Supplement P4.187, 2012. e-Pub 2012.
Paker AM, Chi L, Kamiya-Matsuoka C, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients 13(3):iii26–iii29, 2011. e-Pub 2011.
Inga E, Lopez G, Kamiya-Matsuoka C. Biological accidents in medical students of the Major National University of San Marcos: prevalence, mechanisms and risk factors, 2005. e-Pub 2005.
Kamiya-Matsuoka C. Perception of the Medical Students and Attending Physicians of the Major National University of San Marcos about Animal Experimentation, 2005. e-Pub 2005.
Kamiya-Matsuoka C. Anatomic variants of Celiac Trunk, 2003. e-Pub 2003.
Kamiya-Matsuoka C. Citoprotective effect of the epidermic growth factor in renal ischemia reperfusion injury, 2002. e-Pub 2002.
Kamiya-Matsuoka C. Protein-Energetic Malnutrition of the mother during the prenatal and postnatal period produces alterations in the development of offspring’s brain, 2001. e-Pub 2001.
Sloan AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N, Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M, Mehta MP. NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma 26(9):1628-1637. PMID: 38874333.
Garcia CR, Highsmith KN, Knight S, Puduvalli VK, Kamiya-Matsuoka AC. Single center experience of IDH inhibitors in high-grade gliomas. ASCO 42(Suppl 16).
Floyd JR, Patel TR, Bao A, Phillips W, Michalek J, Huang S, Youssef M, Weinberg JS, Matsuoka CK, Moore M, Blouw B, Juverdianu L, Hedrick M, LaFrance N, Brenner A. Treatment of Recurrent Glioblastoma (rGBM) via Convection Enhanced Delivery (CED) with Rhenium (186Re) Obisbemeda (Rhenium-186 Nanoliposome, 186RNL): ReSPECT-GBM Phase 2 Trial Update. CNS.
Patel AD, Aaroe A, Kamiya-Matsuoka C, Lin R, Majd N, O'Brien BJ, Patel CB, Weathers SS, K Puduvalli AV. Dual Targeting of VEGF and PD-1: A phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma. ASCO.
Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW, Strowd RE, Desjardins A, Kumthekar P, Mason W, Pellerino A, Soffietti R, Butowski N, Forsyth PA, Hamza MA, Hau P, Lallana E, Nabors B, Piccioni D, Uhlmann EJ, Welsh LC, Wen PY, Dietrich J, Wang C, Levin VA. Top-line results of STELLAR, a Phase 3 randomized trial of eflornithine and lomustine vs. lomustine for recurrent/progressive anaplastic astrocytoma 26(Suppl 8):viii1. PMID: 41325560.

Less

CV information above last modified February 03, 2026

Carlos Kamiya Matsuoka, M.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Carlos Kamiya Matsuoka, M.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson